Literature DB >> 18470668

Reference intervals of serum tartrate-resistant acid phosphatase type 5b activity measured with a novel assay in Japanese subjects.

Yoshiki Nishizawa1, Masaaki Inaba, Mitsukazu Ishii, Hiroyuki Yamashita, Takami Miki, Hitoshi Goto, Sinsuke Yamada, Osamu Chaki, Kentaro Kurasawa, Yoshiko Mochizuki.   

Abstract

Among the isotypes of serum tartrate-resistant acid phosphatase (TRACP), only type 5b (TRACP-5b) is derived from osteoclasts, and it is necessary to develop an assay specific for this TRACP-5b for evaluation of osteoclastic activity. Recently, a novel assay system for TRACP-5b called the fragments absorbed immunocapture enzymatic assay (FAICEA) has been developed. With two unique monoclonal antibodies, one that is highly specific for TRACP-5b and another which absorbs inactive TRACP-5b fragments that interfere with measuring active TRACP-5b, this assay provides correct measurement of TRACP-5b activity in the serum without interference by the inactive fragments of TRACP-5b and other isotypes of TRACP, especially TRACP-5a. To study the reference data of Japanese subjects, we measured TRACP-5b activity in the serum of 320 men (age, 20-82 years) and 466 women [315 premenopausal (age, 18-55 years) and 151 postmenopausal (age, 45-77 years)] with this novel assay. In men, serum TRACP-5b activity did not vary significantly with age. The postmenopausal women had significantly higher serum TRACP-5b activity than the premenopausal women. The reference intervals (logarithmic mean +/-1.96 SD) for men, premenopausal women, and postmenopausal women were 1.7-5.9 U/l, 1.2-4.4 U/l, and 2.5-7.6 U/l, respectively.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18470668     DOI: 10.1007/s00774-007-0826-0

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  30 in total

Review 1.  Markers of bone turnover for the prediction of fracture risk.

Authors:  P Garnero
Journal:  Osteoporos Int       Date:  2000       Impact factor: 4.507

2.  Heparin column analysis of serum type 5 tartrate-resistant acid phosphatase isoforms.

Authors:  Y Igarashi; M Y Lee; S Matsuzaki
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2001-06-15

3.  Effects of age, menopause and osteoporosis on free, peptide-bound and total pyridinium crosslink excretion.

Authors:  M T Del Campo; M L González-Casaus; P Aguado; M Bernad; F Carrera; M E Martínez
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

4.  Development of a novel fragments absorbed immunocapture enzyme assay system for tartrate-resistant acid phosphatase 5b.

Authors:  Tatsuya Ohashi; Yoshihiko Igarashi; Yoshiko Mochizuki; Toshihide Miura; Noriyuki Inaba; Katsuhiro Katayama; Takeshi Tomonaga; Fumio Nomura
Journal:  Clin Chim Acta       Date:  2006-08-25       Impact factor: 3.786

5.  High bone turnover is associated with low bone mass in both pre- and postmenopausal women.

Authors:  P Ravn; C Fledelius; C Rosenquist; K Overgaard; C Christiansen
Journal:  Bone       Date:  1996-09       Impact factor: 4.398

6.  Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease.

Authors:  P Garnero; P D Delmas
Journal:  J Clin Endocrinol Metab       Date:  1993-10       Impact factor: 5.958

7.  Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis.

Authors:  Pauling Chu; Tsu-Yi Chao; Yuh-Feng Lin; Anthony J Janckila; Lung T Yam
Journal:  Am J Kidney Dis       Date:  2003-05       Impact factor: 8.860

8.  Urinary excretion of type I collagen crosslinked N-telopeptides in healthy Japanese adults: age- and sex-related changes and reference limits.

Authors:  T Sone; M Miyake; N Takeda; M Fukunaga
Journal:  Bone       Date:  1995-10       Impact factor: 4.398

9.  Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum.

Authors:  B Gomez; S Ardakani; J Ju; D Jenkins; M J Cerelli; G Y Daniloff; V T Kung
Journal:  Clin Chem       Date:  1995-11       Impact factor: 8.327

10.  Characterization and assay of tartrate-resistant acid phosphatase activity in serum: potential use to assess bone resorption.

Authors:  K H Lau; T Onishi; J E Wergedal; F R Singer; D J Baylink
Journal:  Clin Chem       Date:  1987-04       Impact factor: 8.327

View more
  11 in total

1.  Reference intervals of bone turnover markers determined by using their curve-fitting valley for adult females in China.

Authors:  X-Y Wu; H Zhang; H Xie; X-H Luo; Y-Q Peng; L-Q Yuan; R-C Dai; Z-F Sheng; X-P Wu; E-Y Liao
Journal:  Osteoporos Int       Date:  2013-07-23       Impact factor: 4.507

2.  Impact of smoking on bone mineral density and bone metabolism in elderly men: the Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) study.

Authors:  J Tamaki; M Iki; Y Fujita; K Kouda; A Yura; E Kadowaki; Y Sato; J S Moon; K Tomioka; N Okamoto; N Kurumatani
Journal:  Osteoporos Int       Date:  2010-04-10       Impact factor: 4.507

3.  Increased undercarboxylated osteocalcin/intact osteocalcin ratio in patients undergoing hemodialysis.

Authors:  Y Nagata; M Inaba; Y Imanishi; H Okazaki; S Yamada; K Mori; S Shoji; H Koyama; S Okuno
Journal:  Osteoporos Int       Date:  2014-11-18       Impact factor: 4.507

Review 4.  Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition).

Authors:  Yoshiki Nishizawa; Hiroaki Ohta; Masakazu Miura; Masaaki Inaba; Schoichi Ichimura; Masataka Shiraki; Junichi Takada; Osamu Chaki; Hiroshi Hagino; Saeko Fujiwara; Masao Fukunaga; Takami Miki; Noriko Yoshimura
Journal:  J Bone Miner Metab       Date:  2012-11-10       Impact factor: 2.626

5.  Bone turnover markers as an aid to monitor osteoporosis following allogeneic hematopoietic stem cell transplantation.

Authors:  Shuhei Kurosawa; Noriko Doki; Yasushi Senoo; Yuya Kishida; Akihito Nagata; Yuta Yamada; Tatsuya Konishi; Satoshi Kaito; Kota Yoshifuji; Naoki Matsuyama; Shuichi Shirane; Tomoyuki Uchida; Kyoko Inamoto; Takashi Toya; Aiko Igarashi; Yuho Najima; Hideharu Muto; Takeshi Kobayashi; Kazuhiko Kakihana; Hisashi Sakamaki; Kazuteru Ohashi
Journal:  Ann Hematol       Date:  2020-05-25       Impact factor: 3.673

6.  Significant inverse relationship between serum undercarboxylated osteocalcin and glycemic control in maintenance hemodialysis patients.

Authors:  S Okuno; E Ishimura; N Tsuboniwa; K Norimine; K Yamakawa; T Yamakawa; S Shoji; K Mori; Y Nishizawa; M Inaba
Journal:  Osteoporos Int       Date:  2012-05-12       Impact factor: 4.507

7.  Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency.

Authors:  D Miyaoka; Y Imanishi; M Ohara; N Hayashi; Y Nagata; S Yamada; K Mori; M Emoto; M Inaba
Journal:  Osteoporos Int       Date:  2018-09-05       Impact factor: 4.507

8.  (18)F-fluoride positron emission tomography measurements of regional bone formation in hemodialysis patients with suspected adynamic bone disease.

Authors:  Michelle L Frost; Juliet E Compston; David Goldsmith; Amelia E Moore; Glen M Blake; Musib Siddique; Linda Skingle; Ignac Fogelman
Journal:  Calcif Tissue Int       Date:  2013-08-31       Impact factor: 4.333

9.  The Effects of Bazedoxifene on Bone, Glucose, and Lipid Metabolism in Postmenopausal Women With Type 2 Diabetes: An Exploratory Pilot Study.

Authors:  Taishi Yoshii; Masayo Yamada; Taichi Minami; Tetsuji Tsunoda; Mayuko Sasaki; Yoshinobu Kondo; Shinobu Satoh; Yasuo Terauchi
Journal:  J Clin Med Res       Date:  2015-08-23

10.  Long-Term Oral Toxicity and Anti-osteoporotic Effect of Sintered Dicalcium Pyrophosphate in Rat Model of Postmenopausal Osteoporosis.

Authors:  Yuh-Feng Tsai; Li-Ho Hsu; Chang-Chin Wu; Wei-Hua Cai; Kai-Chiang Yang; Fang-Yu Fan
Journal:  J Med Biol Eng       Date:  2017-01-03       Impact factor: 1.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.